Gilead Sciences Inc is a leading biopharmaceutical company focused on developing and commercializing innovative medicines for life-threatening illnesses worldwide. With a strong emphasis on HIV/AIDS, COVID-19, viral hepatitis, and oncology, Gilead offers a range of treatments that address unmet medical needs. Notable products include Biktarvy, Veklury, and Yescarta. Founded in 1987 and based in Foster City, California, Gilead also engages in significant partnerships to advance its research and development efforts.
Gilead is sending shareholders about $1.02 billion in cash, 82 cents a share, landing September 29 and dwarfing every other payment today. Xcel Energy, Ares Capital, T. Rowe Price and Valley National Bancorp round out the biggest checks.
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a…
Chris Lange Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find…
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually…
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave…
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th…
The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story…
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR…
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption.…
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD | GILD Price Prediction) with a Buy rating and a $180 price target,…
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday.…
If a recession were to hit, it’s a foregone conclusion that people won’t stop taking their prescriptions, and they won’t cancel major medical treatments. The same can be said for people who…
Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still…
These four top Bank of America stock picks are now outstanding ideas, and two are in the healthcare sector.
